Duke University

Company snapshot

Duke University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metastatic Breast Cancer, Talaromycosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 3 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Duke University. Not investment advice.

• What is Duke University?

  Duke University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metastatic Breast Cancer, Talaromycosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials

• Is Duke University publicly traded?

  Duke University appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Duke University develop or market?

  We link 5 drug profile(s) where Duke University is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/duke-university#company-drugs.

• What are the latest developments for Duke University?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Duke University focus on?

  Duke University focuses on Metastatic Breast Cancer, Talaromycosis based on our analysis of their pipeline programs and drug development activities.